Advertisement Tosoh Announces Two New Application Notebooks - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
More info about Tosoh Bioscience

Tosoh Announces Two New Application Notebooks

Tosoh is pleased to announce the launch of two new application notebooks.

Bioprocessing Application Notebook

The purification and recovery of a biological target molecule out of a tissue, cell or fermentation broth – the so-called downstream processing (DSP) – usually requires a combination of separation technologies. Bioprocess chromatography is the most important technique for this purpose.

Today, biopharmaceuticals are the fastest growing product segment of the pharmaceutical industry. An effective and affordable purification of therapeutic biomolecules is key for the successful development and commercialization of new drugs, no matter whether biologic, biosimilar, or biobetter. With new biopharmaceutical formats, such as bispecific mAbs, antibody fragments and antibody-drug-conjugates (ADCs) in the pipeline, rapid development of DSP steps will become even more important.

Tosoh’s Bioprocessing Application Notebook compiles over twenty application notes covering important aspects of biopharmaceutical purification such as capturing of antibody constructs (e.g. Fab, scFv, or mAB), mAb aggregate removal using salt-tolerant IEC or hydroxyapatite, intermediate purification of bi-specific antibodies with a non-affinity platform using MXC and HIC, antibody-drug conjugates (ADC) purification on HIC resin, or separation of oligonucleotides on highly-selective anion exchanger.

U/HPLC Application Notebook for Biotech & Biopharmaceuticals

Biological drugs are indispensable in the treatment of many serious diseases. Thorough characterisation is the key to successful approval, whether biologic, biosimilar or biobetter.

Quality control also requires effective tools to determine the critical quality characteristics of different types of biopharmaceuticals, be they monoclonal antibodies (mAbs), other therapeutic proteins or oligonucleotides. With new formats such as bispecific antibodies or antibody-drug conjugates (ADCs) in the pipeline also increases the complexity of analytics.

The white paper bundles applications on important aspects of biopharmaceutical analysis using HPLC, UHPLC and LC-MS.

Read the whitepaper to learn more:

  • Which separation principles can be used for biopharmaceuticals
  • How to efficiently analyze recombinant therapeutic proteins / antibodies
  • How to transfer methods from HPLC to UHPLC